Therapixel announces launch of prospective study on the utility of Artificial Intelligence (AI) as part of second reading breast cancer screening mammograms

The first French prospective clinical study to evaluate the contribution of AI in the second reading of screening mammograms.

Therapixel releases a new version of MammoScreen® that leverages prior exams for better accuracy

For the first time, an AI-based decision support software for breast cancer detection uses patient’s prior exams to refine its prediction of malignancy

Therapixel announces close of 15 M€ series B financing to deploy MammoScreen® 2D/3D

The Company will accelerate the commercial deployment of its Artificial Intelligence reading solution for 2D/3D mammography, with a focus on the United States

Therapixel receives FDA clearance for use of its AI-based breast cancer screening software MammoScreen® on Digital Breast Tomosynthesis

AI-powered reading aid for screening 2D & 3D mammography improves Radiologists’ performance in cancer detection

Therapixel-presents-MammoScreen-ECR 2021

Therapixel will be showcasing MammoScreen™ at the virtual ECR 2021

Stop by our booth to learn more about our FDA-cleared and newly CE-marked AI for breast cancer screening

CE Marking

Therapixel receives the CE mark for its Artificial Intelligence-based software (AI) MammoScreen™

This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately.